Fibrogen Inc CS (FGEN) said after close Monday that it lost $0.52 per share in quarter three 2023. The company reported earnings on an adjusted basis, so it may not be directly comparable to analyst estimates or prior periods.
On the revenue line, the company reported $40.1 million, beating estimates by $3.3 million.
In the same quarter a year ago, the company lost $0.98 per share on revenue of $15.7 million.
The stock is up 11.77% to $0.63 after the report.
Despite revenues increasing, earnings decreased, signaling a decline in profit margins.
Wall Street Analysts had an average rating of Sell on the stock prior to the report.
Trading in the five days leading up to the report earned Fibrogen Inc CS a Bearish Sentiment Rank from InvestorsObserver.
Fibrogen Inc CS has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 2, putting Fibrogen Inc CS in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $0.47 on October 30, 2023 and set a 52-week high on February 3, 2023 at $25.69.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
News Home
Fibrogen Inc CS Up 11.77% To $0.63 After Earnings Beat
Mentioned in this article
